EVT-101
 | |
| Clinical data | |
|---|---|
| Other names | ENS-101 |
| Drug class | NMDA receptor antagonist |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H13F3N4 |
| Molar mass | 318.303 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] The drug was first claimed by Roche in 2002.[3] By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.[1]
See also
[edit]References
[edit]- ^ a b c "EVT 101 - AdisInsight".
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2017-08-29. Retrieved 2018-02-10.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (2012). "Novel NMDA receptor modulators: an update". Expert Opin Ther Pat. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |